These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 19640854)

  • 1. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Fouque-Aubert A; Jette-Paulin L; Combescure C; Basch A; Tebib J; Gossec L
    Ann Rheum Dis; 2010 Oct; 69(10):1756-61. PubMed ID: 19640854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.
    Minozzi S; Bonovas S; Lytras T; Pecoraro V; González-Lorenzo M; Bastiampillai AJ; Gabrielli EM; Lonati AC; Moja L; Cinquini M; Marino V; Matucci A; Milano GM; Tocci G; Scarpa R; Goletti D; Cantini F
    Expert Opin Drug Saf; 2016 Dec; 15(sup1):11-34. PubMed ID: 27924643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.
    Bongartz T; Sutton AJ; Sweeting MJ; Buchan I; Matteson EL; Montori V
    JAMA; 2006 May; 295(19):2275-85. PubMed ID: 16705109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.
    Salliot C; Dougados M; Gossec L
    Ann Rheum Dis; 2009 Jan; 68(1):25-32. PubMed ID: 18203761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indirect comparison of the effects of anti-TNF biological agents in patients with ankylosing spondylitis by means of a mixed treatment comparison performed on efficacy data from published randomised, controlled trials.
    Migliore A; Broccoli S; Bizzi E; Laganà B
    J Med Econ; 2012; 15(3):473-80. PubMed ID: 22335398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.
    van der Heijde D; Zack D; Wajdula J; Sridharan S; Koenig AS
    Scand J Rheumatol; 2014; 43(1):49-53. PubMed ID: 24182312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Singh JA; Cameron C; Noorbaloochi S; Cullis T; Tucker M; Christensen R; Ghogomu ET; Coyle D; Clifford T; Tugwell P; Wells GA
    Lancet; 2015 Jul; 386(9990):258-65. PubMed ID: 25975452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients.
    Salliot C; Gossec L; Ruyssen-Witrand A; Luc M; Duclos M; Guignard S; Dougados M
    Rheumatology (Oxford); 2007 Feb; 46(2):327-34. PubMed ID: 16880188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP; Einarson TR; Keystone EC
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis.
    Escalas C; Trijau S; Dougados M
    Rheumatology (Oxford); 2010 Jul; 49(7):1317-25. PubMed ID: 20360041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures?
    Nannini C; Cantini F; Niccoli L; Cassarà E; Salvarani C; Olivieri I; Lally EV
    Arthritis Rheum; 2009 Jun; 61(6):801-12. PubMed ID: 19479708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
    Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis.
    Baraliakos X; van den Berg R; Braun J; van der Heijde D
    Rheumatology (Oxford); 2012 Aug; 51(8):1378-87. PubMed ID: 22427410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological treatment of ankylosing spondylitis: a systematic review.
    Boulos P; Dougados M; Macleod SM; Hunsche E
    Drugs; 2005; 65(15):2111-27. PubMed ID: 16225367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis.
    Wu D; Guo YY; Xu NN; Zhao S; Hou LX; Jiao T; Zhang N
    BMC Musculoskelet Disord; 2015 Feb; 16(1):19. PubMed ID: 25888248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.